# Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct04146298/  
OnCo record `nct04146298` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of cyclophosphamide and fludarabine in pancreatic cancer, run by Changhai Hospital, now recruiting.

## Summary

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer is a phase 1/2, interventional study registered as NCT04146298 by Changhai Hospital, with a registry enrolment figure of 30 participants, started 2021-10-21 and due to reach its primary completion in 2027-06. Interventions recorded: Cyclophosphamide; Fludarabine; Mutant KRAS G12V-specific TCR transduced autologous T cells; Anti-PD-1 monoclonal antibody. Conditions listed: Pancreatic Cancer; Pancreatic Neoplasms; Pancreatic Ductal Adenocarcinoma; Advanced Cancer. Primary outcome: Frequency and severity of treatment-related adverse events; Objective response rate. Pancreatic eligibility wording from the registry: "* Patients with measurable and pathologically confirmed advanced pancreatic cancer, including metastatic pancreatic cancer (who have received standard chemotherapy) and recurrent pancreatic cancer (who have received surgery and adjuvant chemotherapy previously)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT04146298
- Phase: 1/2
- Setting: Clinical Trial Evaluating the Safety and Activity of Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
- Sponsor: Changhai Hospital
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT04146298: https://clinicaltrials.gov/study/NCT04146298

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04146298.json